In the latest move to curb the nation's opioid crisis, health insurer Cigna Corp. has announced it will stop covering prescriptions for OxyContin, a prescription opioid that has a high risk of addiction.
"Our focus is on helping customers get the most value from their medications – this means obtaining effective pain relief while also guarding against opioid misuse," Jon Maesner, Cigna's chief pharmacy officer, said in a press release. "We continually evaluate the clinical effectiveness, affordability, and safety of all our covered medications as these characteristics can change over time, and we make adjustments that we believe will provide better overall value for those we serve."
Instead, the company will offer Xtampza ER, a slow-release oxycodone equivalent that cannot be augmented to increase potency and is thus less susceptible to abuse. Cigna's agreement with the manufacturer, Collegium Pharmaceutical, also holds the company responsible if the average dosage prescribed is above a set threshold. The incentive, Cigna hopes, will discourage overprescribing and is part of the insurer's plan to cut opioid use among its customers by 25 percent by 2019.
Recommended For You
"While drug companies don't control prescriptions, they can help influence patient and doctor conversations by educating people about their medications. The insights we obtain from the metrics in the new value-based contract will help us continue to evolve our opioid management strategies to assist our customers and their doctors," Maesner said.
Cigna will continue to offer OxyContin to some patients currently taking the medication—those on hospice care or undergoing cancer treatment, or patients whose providers feel it is medically necessary. Other patients will have
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.